LONG MINI-FUTURE - GENMAB | Real-time Bid/Ask 07:47:05 25/06/2024 BST | ||
| 10.43 EUR / 11.15 EUR | -3.83% |
|
| Current month | -9.81% | ||
| 1 month | -18.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 25/06/24 | 10.4 | -7.31% |
| 24/06/24 | 11.22 | +9.46% |
| 20/06/24 | 10.25 | -5.27% |
| 19/06/24 | 10.82 | +1.31% |
| 18/06/24 | 10.68 | -2.11% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 07:26 am
More quotesStatic data
| Product type | Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VA80VM |
| ISIN | DE000VA80VM4 |
| Date issued | 30/10/2018 |
| Strike | 988.7 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.79 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 32.6 € |
|---|---|
| Lowest since issue | 1.46 € |
| Spread | 0.72 € |
| Spread % | 6.45% |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,805
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.51%
- Stock Market
- Certificates
- Certificat
